23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › IOVANCE BIOTHERAPEUTICS INC. › 2023-2024

IOVANCE BIOTHERAPEUTICS INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and IOVANCE BIOTHERAPEUTICS INC.’s Form 8-K, filed June 11, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 11Reported items
  • 271Asset managers, any item
  • 2,620Fund votes
  • June 11, 2024Meeting date

Results at a glance

Meeting of June 11, 2024: 11 items on IOVANCE BIOTHERAPEUTICS INC.’s Form 8-K, filed June 11, 2024: 4 approved · 7 passed (calculated).

Dissent

Notable dissent: 1 director (14.5% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore IOVANCE BIOTHERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by IOVANCE BIOTHERAPEUTICS INC.

These tallies are IOVANCE BIOTHERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 11, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

IOVANCE BIOTHERAPEUTICS INC. — official shareholder meeting results, meeting held June 11, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Dr. Dukes 158,014,469---- 26,837,80840,390,510 85%Passed (calculated)—
Elect Director: Dr. Countouriotis 179,910,972---- 4,941,30540,390,510 97%Passed (calculated)—
Elect Director: Mr. Maynard 181,374,341---- 3,477,93640,390,510 98%Passed (calculated)—
Elect Director: Mr. Rothbaum 182,486,148---- 2,366,12940,390,510 99%Passed (calculated)—
Elect Director: Dr. Vogt 183,635,378---- 1,216,89940,390,510 99.3%Passed (calculated)—
Elect Director: Dr. Weiser 177,964,197---- 6,888,08040,390,510 96%Passed (calculated)—
Elect Director: Ms. Yarno 182,153,723---- 2,698,55440,390,510 99%Passed (calculated)—
This proposal was approved with 173,751,712 "FOR" votes, 10,032,612 "AGAINST" votes and 1,067,953 "ABSTAIN" votes 173,751,71210,032,6121,067,953 --40,390,510 95%Approved—
This proposal was approved with 223,631,459 "FOR" votes, 396,153 "AGAINST" votes and 1,215,175 "ABSTAIN" votes 223,631,459396,1531,215,175 --0 99.8%Approved—
This proposal was approved with 177,464,536 "FOR" votes, 6,660,260 "AGAINST" votes and 727,481 "ABSTAIN" votes 177,464,5366,660,260727,481 --40,390,510 96%Approved—
This proposal was approved with 182,042,189 "FOR" votes, 2,433,346 "AGAINST" votes and 376,742 "ABSTAIN" votes 182,042,1892,433,346376,742 --40,390,510 99%Approved—

Source: IOVANCE BIOTHERAPEUTICS INC., Form 8-K, filed with the SEC on June 11, 2024 — read the filing on EDGAR.

How asset managers voted at the IOVANCE BIOTHERAPEUTICS INC. 2023-2024 meeting

271 asset managers disclosed a vote on at least one IOVANCE BIOTHERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of IOVANCE BIOTHERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

Elect Director: Dr. Countouriotis

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 179,910,972WITHHELD: 4,941,305

Prior year: 89.1% for (June 6, 2023 meeting) ▲ 8.2 pts

Details: description as filed, official tally, votes by 71 asset managers

Description as filed by funds: To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual Meeting of Stockholders: Athena Countouriotis, M.D.

IOVANCE BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Dr. Countouriotis”): 179,910,972 for, 4,941,305 withheld, per its Form 8-K filed June 11, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 71 asset managers below reported 54,364,980 for, 569,542 withheld, 21,685 abstained.

FOR
FOR: 54,364,980ABSTAIN: 21,685WITHHOLD: 569,542
Largest asset managers voting on “To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual ” at IOVANCE BIOTHERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard24,534,3080 00For
T. Rowe Price5,256,3610 00For
BlackRock5,241,4170 00For
State Street3,896,7210 0902For
Fidelity2,707,5430 033,121For
Artisan2,609,9460 00For
Charles Schwab1,923,3190 00For
TIAA1,643,0890 00For
Dimensional730,4220 00For
Equitable397,6430 0261,740Mixed
Principal627,5970 00For
JPMorgan456,1880 00For
Goldman Sachs413,7790 00For
QUANTITATIVE MASTER SERIES LLC378,8140 00For
Direxion Shares ETF Trust376,0600 00For
Manager Directed Portfolios358,0330 00For
AIG/SunAmerica232,9960 00For
Lincoln Financial223,3640 00For
SEI205,2270 00For
John Hancock200,2280 00For
Virtus191,9410 00For
ProShares141,5080 00For
DRIEHAUS MUTUAL FUNDS135,9540 00For
Bridge Builder Trust96,5950 21,6850Mixed
Global X109,0780 00For

Showing the 25 largest of 71 asset managers. All 71 are in the interactive database (link above).

Elect Director: Dr. Vogt

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99.3% Majority: yes · of votes cast

FOR 99.3%
FOR: 183,635,378WITHHELD: 1,216,899
Details: description as filed, official tally, votes by 71 asset managers

Description as filed by funds: To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual Meeting of Stockholders: Frederick G. Vogt, Ph.D., J.D.

IOVANCE BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Dr. Vogt”): 183,635,378 for, 1,216,899 withheld, per its Form 8-K filed June 11, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99.3% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 71 asset managers below reported 54,956,207 for.

FOR
FOR: 54,956,207
Largest asset managers voting on “To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual ” at IOVANCE BIOTHERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard24,534,3080 00For
T. Rowe Price5,256,3610 00For
BlackRock5,241,4170 00For
State Street3,897,6230 00For
Fidelity2,740,6640 00For
Artisan2,609,9460 00For
Charles Schwab1,923,3190 00For
TIAA1,643,0890 00For
Dimensional730,4220 00For
Equitable659,3830 00For
Principal627,5970 00For
JPMorgan456,1880 00For
Goldman Sachs413,7790 00For
QUANTITATIVE MASTER SERIES LLC378,8140 00For
Direxion Shares ETF Trust376,0600 00For
Manager Directed Portfolios358,0330 00For
AIG/SunAmerica232,9960 00For
Lincoln Financial223,3640 00For
SEI205,2270 00For
John Hancock200,2280 00For
Virtus191,9410 00For
ProShares141,5080 00For
DRIEHAUS MUTUAL FUNDS135,9540 00For
Bridge Builder Trust118,2800 00For
Global X109,0780 00For

Showing the 25 largest of 71 asset managers. All 71 are in the interactive database (link above).

Elect Director: Dr. Dukes

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

85% Majority: yes · of votes cast

FOR 85%WITHHELD
FOR: 158,014,469WITHHELD: 26,837,808

Prior year: 87.3% for (June 6, 2023 meeting) ▼ 1.8 pts

Details: description as filed, official tally, votes by 71 asset managers

Description as filed by funds: To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual Meeting of Stockholders: Iain Dukes, D. Phil.

IOVANCE BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Dr. Dukes”): 158,014,469 for, 26,837,808 withheld, per its Form 8-K filed June 11, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 71 asset managers below reported 48,518,794 for, 5,808,744 withheld, 628,669 abstained.

FOR
FOR: 48,518,794ABSTAIN: 628,669WITHHOLD: 5,808,744
Largest asset managers voting on “To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual ” at IOVANCE BIOTHERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard24,534,3080 00For
T. Rowe Price5,256,3610 00For
BlackRock5,241,4170 00For
State Street3,892,0980 05,525For
Fidelity2,707,5430 033,121For
Artisan00 02,609,946Withhold
Charles Schwab1,923,3190 00For
TIAA1,643,0890 00For
Dimensional730,4220 00For
Equitable397,6430 0261,740Mixed
Principal5450 0627,052Withhold
JPMorgan00 456,1880Abstain
Goldman Sachs413,7790 00For
QUANTITATIVE MASTER SERIES LLC378,8140 00For
Direxion Shares ETF Trust00 0376,060Withhold
Manager Directed Portfolios358,0330 00For
AIG/SunAmerica00 0232,996Withhold
Lincoln Financial208,3060 015,058Mixed
SEI00 0205,227Withhold
John Hancock112,8060 87,4220Mixed
Virtus00 0191,941Withhold
ProShares00 0141,508Withhold
DRIEHAUS MUTUAL FUNDS00 0135,954Withhold
Bridge Builder Trust96,5950 21,6850Mixed
Global X00 0109,078Withhold

Showing the 25 largest of 71 asset managers. All 71 are in the interactive database (link above).

Elect Director: Dr. Weiser

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 177,964,197WITHHELD: 6,888,080

Prior year: 87.0% for (June 6, 2023 meeting) ▲ 9.3 pts

Details: description as filed, official tally, votes by 71 asset managers

Description as filed by funds: To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual Meeting of Stockholders: Michael Weiser M.D., Ph.D.

IOVANCE BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Dr. Weiser”): 177,964,197 for, 6,888,080 withheld, per its Form 8-K filed June 11, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 71 asset managers below reported 54,364,980 for, 569,542 withheld, 21,685 abstained.

FOR
FOR: 54,364,980ABSTAIN: 21,685WITHHOLD: 569,542
Largest asset managers voting on “To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual ” at IOVANCE BIOTHERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard24,534,3080 00For
T. Rowe Price5,256,3610 00For
BlackRock5,241,4170 00For
State Street3,896,7210 0902For
Fidelity2,707,5430 033,121For
Artisan2,609,9460 00For
Charles Schwab1,923,3190 00For
TIAA1,643,0890 00For
Dimensional730,4220 00For
Equitable397,6430 0261,740Mixed
Principal627,5970 00For
JPMorgan456,1880 00For
Goldman Sachs413,7790 00For
QUANTITATIVE MASTER SERIES LLC378,8140 00For
Direxion Shares ETF Trust376,0600 00For
Manager Directed Portfolios358,0330 00For
AIG/SunAmerica232,9960 00For
Lincoln Financial223,3640 00For
SEI205,2270 00For
John Hancock200,2280 00For
Virtus191,9410 00For
ProShares141,5080 00For
DRIEHAUS MUTUAL FUNDS135,9540 00For
Bridge Builder Trust96,5950 21,6850Mixed
Global X109,0780 00For

Showing the 25 largest of 71 asset managers. All 71 are in the interactive database (link above).

Elect Director: Mr. Maynard

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 181,374,341WITHHELD: 3,477,936

Prior year: 90.8% for (June 6, 2023 meeting) ▲ 7.3 pts

Details: description as filed, official tally, votes by 71 asset managers

Description as filed by funds: To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual Meeting of Stockholders: Ryan Maynard

IOVANCE BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Mr. Maynard”): 181,374,341 for, 3,477,936 withheld, per its Form 8-K filed June 11, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 71 asset managers below reported 54,955,796 for, 411 withheld.

FOR
FOR: 54,955,796WITHHOLD: 411
Largest asset managers voting on “To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual ” at IOVANCE BIOTHERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard24,534,3080 00For
T. Rowe Price5,256,3610 00For
BlackRock5,241,4170 00For
State Street3,897,2120 0411For
Fidelity2,740,6640 00For
Artisan2,609,9460 00For
Charles Schwab1,923,3190 00For
TIAA1,643,0890 00For
Dimensional730,4220 00For
Equitable659,3830 00For
Principal627,5970 00For
JPMorgan456,1880 00For
Goldman Sachs413,7790 00For
QUANTITATIVE MASTER SERIES LLC378,8140 00For
Direxion Shares ETF Trust376,0600 00For
Manager Directed Portfolios358,0330 00For
AIG/SunAmerica232,9960 00For
Lincoln Financial223,3640 00For
SEI205,2270 00For
John Hancock200,2280 00For
Virtus191,9410 00For
ProShares141,5080 00For
DRIEHAUS MUTUAL FUNDS135,9540 00For
Bridge Builder Trust118,2800 00For
Global X109,0780 00For

Showing the 25 largest of 71 asset managers. All 71 are in the interactive database (link above).

Elect Director: Mr. Rothbaum

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 182,486,148WITHHELD: 2,366,129

Prior year: 90.8% for (June 6, 2023 meeting) ▲ 7.9 pts

Details: description as filed, official tally, votes by 71 asset managers

Description as filed by funds: To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual Meeting of Stockholders: Wayne P. Rothbaum

IOVANCE BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Mr. Rothbaum”): 182,486,148 for, 2,366,129 withheld, per its Form 8-K filed June 11, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 71 asset managers below reported 54,955,796 for, 411 withheld.

FOR
FOR: 54,955,796WITHHOLD: 411
Largest asset managers voting on “To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual ” at IOVANCE BIOTHERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard24,534,3080 00For
T. Rowe Price5,256,3610 00For
BlackRock5,241,4170 00For
State Street3,897,2120 0411For
Fidelity2,740,6640 00For
Artisan2,609,9460 00For
Charles Schwab1,923,3190 00For
TIAA1,643,0890 00For
Dimensional730,4220 00For
Equitable659,3830 00For
Principal627,5970 00For
JPMorgan456,1880 00For
Goldman Sachs413,7790 00For
QUANTITATIVE MASTER SERIES LLC378,8140 00For
Direxion Shares ETF Trust376,0600 00For
Manager Directed Portfolios358,0330 00For
AIG/SunAmerica232,9960 00For
Lincoln Financial223,3640 00For
SEI205,2270 00For
John Hancock200,2280 00For
Virtus191,9410 00For
ProShares141,5080 00For
DRIEHAUS MUTUAL FUNDS135,9540 00For
Bridge Builder Trust118,2800 00For
Global X109,0780 00For

Showing the 25 largest of 71 asset managers. All 71 are in the interactive database (link above).

Elect Director: Ms. Yarno

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 182,153,723WITHHELD: 2,698,554

Prior year: 87.3% for (June 6, 2023 meeting) ▲ 11.3 pts

Details: description as filed, official tally, votes by 71 asset managers

Description as filed by funds: To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual Meeting of Stockholders: Wendy Yarno

IOVANCE BIOTHERAPEUTICS INC.’s own tally for this item (“Elect Director: Ms. Yarno”): 182,153,723 for, 2,698,554 withheld, per its Form 8-K filed June 11, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 71 asset managers below reported 54,955,796 for, 411 withheld.

FOR
FOR: 54,955,796WITHHOLD: 411
Largest asset managers voting on “To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual ” at IOVANCE BIOTHERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard24,534,3080 00For
T. Rowe Price5,256,3610 00For
BlackRock5,241,4170 00For
State Street3,897,2120 0411For
Fidelity2,740,6640 00For
Artisan2,609,9460 00For
Charles Schwab1,923,3190 00For
TIAA1,643,0890 00For
Dimensional730,4220 00For
Equitable659,3830 00For
Principal627,5970 00For
JPMorgan456,1880 00For
Goldman Sachs413,7790 00For
QUANTITATIVE MASTER SERIES LLC378,8140 00For
Direxion Shares ETF Trust376,0600 00For
Manager Directed Portfolios358,0330 00For
AIG/SunAmerica232,9960 00For
Lincoln Financial223,3640 00For
SEI205,2270 00For
John Hancock200,2280 00For
Virtus191,9410 00For
ProShares141,5080 00For
DRIEHAUS MUTUAL FUNDS135,9540 00For
Bridge Builder Trust118,2800 00For
Global X109,0780 00For

Showing the 25 largest of 71 asset managers. All 71 are in the interactive database (link above).

To approve an amendment to our 2020 Employee Stock Purchase Plan to increase the number of shares of the Company's…

No official matchCOMPENSATION

Combines 3 wordings of this item as funds reported it.

100% of fund votes cast · no official result

FOR
Details: description as filed, votes by 71 asset managers

Description as filed by funds: To approve an amendment to our 2020 Employee Stock Purchase Plan to increase the number of shares of the Company's common stock authorized for issuance thereunder from 1,400,000 shares to 1,900,000 shares.

The 71 asset managers below reported 54,956,207 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 54,956,207
Largest asset managers voting on “To approve an amendment to our 2020 Employee Stock Purchase Plan to increase the number of shares of the Compa” at IOVANCE BIOTHERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard24,534,3080 00For
T. Rowe Price5,256,3610 00For
BlackRock5,241,4170 00For
State Street3,897,6230 00For
Fidelity2,740,6640 00For
Artisan2,609,9460 00For
Charles Schwab1,923,3190 00For
TIAA1,643,0890 00For
Dimensional730,4220 00For
Equitable659,3830 00For
Principal627,5970 00For
JPMorgan456,1880 00For
Goldman Sachs413,7790 00For
QUANTITATIVE MASTER SERIES LLC378,8140 00For
Direxion Shares ETF Trust376,0600 00For
Manager Directed Portfolios358,0330 00For
AIG/SunAmerica232,9960 00For
Lincoln Financial223,3640 00For
SEI205,2270 00For
John Hancock200,2280 00For
Virtus191,9410 00For
ProShares141,5080 00For
DRIEHAUS MUTUAL FUNDS135,9540 00For
Bridge Builder Trust118,2800 00For
Global X109,0780 00For

Showing the 25 largest of 71 asset managers. All 71 are in the interactive database (link above).

To approve an amendment to our 2018 Equity Incentive Plan to increase the number of shares of the Company's common…

No official matchCOMPENSATION

99.9% of fund votes cast · no official result

FOR
Details: description as filed, votes by 65 asset managers

Description as filed by funds: To approve an amendment to our 2018 Equity Incentive Plan to increase the number of shares of the Company's common stock authorized for issuance thereunder from 29,700,000 shares to 36,700,000 shares and permit share recapture from our 2014 Equity Incentive Plan; and

The 65 asset managers below reported 52,551,314 for, 74,959 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 52,551,314AGAINST: 74,959
Largest asset managers voting on “To approve an amendment to our 2018 Equity Incentive Plan to increase the number of shares of the Company's co” at IOVANCE BIOTHERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard24,534,3080 00For
T. Rowe Price5,256,3610 00For
BlackRock5,241,4170 00For
State Street3,897,474149 00For
Fidelity2,740,6640 00For
Artisan2,609,9460 00For
TIAA1,643,0890 00For
Dimensional730,4220 00For
Equitable659,3830 00For
Principal627,0520 00For
JPMorgan456,1880 00For
Goldman Sachs413,7790 00For
QUANTITATIVE MASTER SERIES LLC378,8140 00For
Direxion Shares ETF Trust376,0600 00For
Manager Directed Portfolios358,0330 00For
AIG/SunAmerica232,9960 00For
Lincoln Financial223,3640 00For
John Hancock200,2280 00For
Virtus191,9410 00For
ProShares141,5080 00For
DRIEHAUS MUTUAL FUNDS135,9540 00For
Bridge Builder Trust118,2800 00For
Northern Trust102,5220 00For
Prudential/PGIM100,1860 00For
Pacific Life95,6170 00For

Showing the 25 largest of 65 asset managers. All 65 are in the interactive database (link above).

To approve, by non-binding advisory vote, the compensation of our named executive officers

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 7 wordings of this item as funds reported it.

94% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: description as filed, votes by 269 asset managers

Description as filed by funds: To approve, by non-binding advisory vote, the compensation of our named executive officers;

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 71 asset managers voting on “To approve, by non-binding advisory vote, the compensation of our named executive officers;” at IOVANCE BIOTHERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard24,534,3080 00For
Artisan6,318,8740 00For
T. Rowe Price5,256,3610 00For
BlackRock5,241,4170 00For
State Street3,896,721902 00For
Fidelity2,740,6640 00For
Charles Schwab1,923,3190 00For
TIAA1,643,0890 00For
Dimensional730,4220 00For
Equitable659,3830 00For
Principal627,5970 00For
JPMorgan456,1880 00For
Goldman Sachs413,7790 00For
QUANTITATIVE MASTER SERIES LLC378,8140 00For
Direxion Shares ETF Trust376,0600 00For
Manager Directed Portfolios358,0330 00For
AIG/SunAmerica232,9960 00For
Lincoln Financial223,3640 00For
SEI205,2270 00For
John Hancock200,2280 00For
Virtus191,9410 00For
ProShares141,5080 00For
DRIEHAUS MUTUAL FUNDS135,9540 00For
Bridge Builder Trust118,2800 00For
Global X109,0780 00For

Fund voting reports, all 71 managers: 58,342,811 for, 322,324 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 214 asset managers voting on “To approve, by non-binding advisory vote, the compensation of our named executive officers;” at IOVANCE BIOTHERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
PERCEPTIVE ADVISORS LLC8,714,4550 00For
State Street8,205,7311,142 00For
T. Rowe Price6,753,8400 00For
BlackRock6,336,56262,914 00For
Avoro Capital Advisors LLC4,050,3160 00For
Soleus Capital Management, L.P.3,992,0280 00For
GEODE CAPITAL MANAGEMENT, LLC2,956,1460 00For
MPM BioImpact LLC2,200,0000 00For
PICTET ASSET MANAGEMENT SA2,191,4840 00For
Palo Alto Investors LP2,116,4030 00For
Charles Schwab1,923,5640 00For
Nuveen1,658,1520 00For
Northern Trust1,655,8200 00For
UBS01,523,769 00Against
DE Shaw1,451,3030 00For
Hood River Capital Management LLC1,431,2740 00For
C WorldWide Asset Management Fondsmaeglerselskab A/S01,260,000 00Against
RICE HALL JAMES & ASSOCIATES, LLC22,4541,194,385 00Against
NEW YORK STATE COMMON RETIREMENT FUND1,164,7340 00For
PRINCIPAL GLOBAL INVESTORS1,037,9460 00For
Candriam S.C.A.0909,180 00Against
Opaleye Management Inc.870,0000 00For
Boxer Capital, LLC750,0000 00For
683 Capital Management, LLC737,1780 00For
Goldman Sachs611,5120 00For

Institutional-manager reports, all 214 managers: 68,162,201 for, 7,461,970 against, 108,383 abstained. Showing the 25 largest; every one is in the interactive database (link above).

To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year…

No official matchAUDIT-RELATED

Combines 3 wordings of this item as funds reported it.

100% of fund votes cast · no official result

FOR
Details: description as filed, votes by 71 asset managers

Description as filed by funds: To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024;

The 71 asset managers below reported 54,956,207 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 54,956,207
Largest asset managers voting on “To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fi” at IOVANCE BIOTHERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard24,534,3080 00For
T. Rowe Price5,256,3610 00For
BlackRock5,241,4170 00For
State Street3,897,6230 00For
Fidelity2,740,6640 00For
Artisan2,609,9460 00For
Charles Schwab1,923,3190 00For
TIAA1,643,0890 00For
Dimensional730,4220 00For
Equitable659,3830 00For
Principal627,5970 00For
JPMorgan456,1880 00For
Goldman Sachs413,7790 00For
QUANTITATIVE MASTER SERIES LLC378,8140 00For
Direxion Shares ETF Trust376,0600 00For
Manager Directed Portfolios358,0330 00For
AIG/SunAmerica232,9960 00For
Lincoln Financial223,3640 00For
SEI205,2270 00For
John Hancock200,2280 00For
Virtus191,9410 00For
ProShares141,5080 00For
DRIEHAUS MUTUAL FUNDS135,9540 00For
Bridge Builder Trust118,2800 00For
Global X109,0780 00For

Showing the 25 largest of 71 asset managers. All 71 are in the interactive database (link above).

Largest IOVANCE BIOTHERAPEUTICS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 279,756,339 shares outstanding at the time of that meeting.

Fund voting reports: top IOVANCE BIOTHERAPEUTICS INC. shareholders by shares voted on “To approve, by non-binding advisory vote, the compensation of our named executive officers;”, 2023-2024
#Asset manager % of shares outstanding
1Vanguard 8.77%
2Artisan 2.26%
3T. Rowe Price 1.88%
4BlackRock 1.87%
5State Street 1.39%
6Fidelity 0.98%
7Charles Schwab 0.69%
8TIAA 0.59%
9Dimensional 0.26%
10Equitable 0.24%
Institutional-manager reports: top IOVANCE BIOTHERAPEUTICS INC. shareholders by shares voted on “To approve, by non-binding advisory vote, the compensation of our named executive officers;”, 2023-2024
#Asset manager % of shares outstanding
1PERCEPTIVE ADVISORS LLC 3.12%
2State Street 2.93%
3T. Rowe Price 2.41%
4BlackRock 2.29%
5Avoro Capital Advisors LLC 1.45%
6Soleus Capital Management, L.P. 1.43%
7GEODE CAPITAL MANAGEMENT, LLC 1.06%
8MPM BioImpact LLC 0.79%
9PICTET ASSET MANAGEMENT SA 0.78%
10Palo Alto Investors LP 0.76%

Reported IOVANCE BIOTHERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

IOVANCE BIOTHERAPEUTICS INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
New York, NY30,000,000 10.72%Proxy statement (DEF 14A), proxy filed April 29, 2024
Wayne Rothbaum30,000,000 10.72%Proxy statement (DEF 14A), proxy filed April 29, 2024
BlackRock25,956,289 9.28%Form 13F, quarter ended March 31, 2024
Vanguard Group24,058,983 8.60%Form 13F, quarter ended March 31, 2024
Malvern, PA22,812,820 8.15%Proxy statement (DEF 14A), proxy filed April 29, 2024
Boston, MA16,424,388 5.87%Proxy statement (DEF 14A), proxy filed April 29, 2024
State Street10,402,719 3.72%Form 13F, quarter ended March 31, 2024
Goldman Sachs6,575,502 2.35%Form 13F, quarter ended March 31, 2024
Morgan Stanley5,581,563 2.00%Form 13F, quarter ended March 31, 2024
Geode Capital5,506,617 1.97%Form 13F, quarter ended March 31, 2024

Percentages above are of 279,756,339 shares outstanding, as reported by IOVANCE BIOTHERAPEUTICS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At IOVANCE BIOTHERAPEUTICS INC.'s shareholder meeting held June 11, 2024, in the 2023-2024 proxy season, 271 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 2,620 separate fund positions. Their filings are grouped here into 11 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. IOVANCE BIOTHERAPEUTICS INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve, by non-binding advisory vote, the compensation of our named executive officers; — the reporting funds and managers cast 94% of the shares they voted in favour (FOR divided by FOR plus AGAINST plus WITHHELD; abstained and unvoted shares are excluded because neither took a side). Fund and manager reports are combined in it and may count the same shares twice: it adds fund reports to institutional-manager reports, which can cover the same shares. It is not the company's certified result.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from IOVANCE BIOTHERAPEUTICS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

IOVANCE BIOTHERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “IOVANCE BIOTHERAPEUTICS (IOVA) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/iovance-biotherapeutics-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.